Akash Tewari
Stock Analyst at Jefferies
(1.95)
# 2,788
Out of 4,818 analysts
60
Total ratings
33.33%
Success rate
-6.01%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $48.69 | +39.66% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $62.74 | +51.42% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $120.54 | +24.44% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $3.19 | +401.57% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $105.76 | +78.71% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $17.54 | +356.10% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $29.57 | +153.64% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $994 → $1,015 | $859.73 | +18.06% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $27.67 | +80.70% | 6 | Apr 9, 2024 | |
| APGE Apogee Therapeutics | Maintains: Buy | $37 → $75 | $37.05 | +102.43% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $14.93 | +107.64% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $32 → $40 | $9.14 | +337.64% | 2 | Dec 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $599.76 | +56.23% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $12 | $2.17 | +453.00% | 2 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $22.78 | +71.20% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $5.67 | +217.46% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $600.51 | -14.57% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.05 | +490.16% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $79.84 | +56.56% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $12.52 | -12.14% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $3.6 | $5.14 | -29.96% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.99 | +754.27% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $40.33 | +85.97% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $319.93 | -52.80% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $37.21 | -24.75% | 3 | Oct 7, 2021 |
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $48.69
Upside: +39.66%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $62.74
Upside: +51.42%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $120.54
Upside: +24.44%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $3.19
Upside: +401.57%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $105.76
Upside: +78.71%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $17.54
Upside: +356.10%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $29.57
Upside: +153.64%
Eli Lilly and Company
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $859.73
Upside: +18.06%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $27.67
Upside: +80.70%
Apogee Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $37.05
Upside: +102.43%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $14.93
Upside: +107.64%
Dec 6, 2023
Upgrades: Buy
Price Target: $32 → $40
Current: $9.14
Upside: +337.64%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $599.76
Upside: +56.23%
Nov 28, 2023
Maintains: Buy
Price Target: $15 → $12
Current: $2.17
Upside: +453.00%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $22.78
Upside: +71.20%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $5.67
Upside: +217.46%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $600.51
Upside: -14.57%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $3.05
Upside: +490.16%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $79.84
Upside: +56.56%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $12.52
Upside: -12.14%
Dec 16, 2022
Downgrades: Hold
Price Target: $30 → $3.6
Current: $5.14
Upside: -29.96%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.99
Upside: +754.27%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $40.33
Upside: +85.97%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $319.93
Upside: -52.80%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $37.21
Upside: -24.75%